Kezar Life Sciences (KZR)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	34.86 mm	34.86 mm	34.86 mm	34.86 mm	34.86 mm	34.86 mm
Cash burn (monthly)	(no burn)	(no burn)	7.32 mm	8.64 mm	5.83 mm	4.87 mm
Cash used (since last report)	n/a	n/a	37.18 mm	43.88 mm	29.63 mm	24.73 mm
Cash remaining	n/a	n/a	-2.32 mm	-9.02 mm	5.23 mm	10.12 mm
Runway (months of cash)	n/a	n/a	-0.3	-1.0	0.9	2.1

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

KZR institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	59	81	-27.2%
Opened positions	6	23	-73.9%
Closed positions	28	28	–
Increased positions	12	17	-29.4%
Reduced positions	23	24	-4.2%

13F shares	Current	Prev Q	Change
Total value	29.32 bn	22.38 bn	+31.0%
Total shares	46.91 mm	48.59 mm	-3.5%
Total puts	600.00	700.00	-14.3%
Total calls	13.80 k	3.20 k	+331.3%
Total put/call ratio	0.0	0.2	-80.1%

Largest owners	Shares	Value	Change
Suvretta Capital Management	7.17 mm	$5.54 bn	0.0%
Morningside Venture Investments	6.25 mm	$9.63 mm	0.0%
Avidity Partners Management	5.03 mm	$3.89 bn	0.0%
Tang Capital Management	3.64 mm	$2.81 bn	NEW
BBBOF BB Biotech	3.00 mm	$0.00	0.0%
Vanguard	2.74 mm	$2.12 bn	0.0%
Affinity Asset Advisors	2.51 mm	$1.94 bn	+42.6%
Orbimed Advisors	1.93 mm	$1.49 bn	0.0%
Acadian Asset Management	1.58 mm	$1.22 mm	-15.0%
Stonepine Capital Management	1.49 mm	$1.15 bn	+42.0%

Largest transactions	Shares	Bought/sold	Change
Tang Capital Management	3.64 mm	+3.64 mm	NEW
Sphera Funds Management	205.17 k	-1.85 mm	-90.0%
ADAR1 Capital Management	0.00	-1.09 mm	EXIT
BLK BlackRock	0.00	-830.37 k	EXIT
BlackRock	828.58 k	+828.58 k	NEW
Affinity Asset Advisors	2.51 mm	+750.00 k	+42.6%
GS The Goldman Sachs Group, Inc.	297.77 k	-721.40 k	-70.8%
Renaissance Technologies	1.30 mm	+518.60 k	+66.6%
Jane Street	59.54 k	-489.52 k	-89.2%
BNP Paribas Arbitrage	0.00	-443.72 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

KZR insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
14 Feb 25	John Franklin Fowler	Stock Option Common Stock	Grant	Acquire A	No	No	5.89	5,000	29.45 k	5,000
9 Jan 25	Christopher J. Kirk	Employee Stock Option Common Stock	Grant	Acquire A	No	No	6.58	120,000	789.60 k	120,000
9 Jan 25	Marc Belsky	Employee Stock Option Common Stock	Grant	Acquire A	No	No	6.58	24,500	161.21 k	24,500
9 Jan 25	Mark C. Schiller	Employee Stock Option Common Stock	Grant	Acquire A	No	No	6.58	24,500	161.21 k	24,500
2 Jul 24	Mark C. Schiller	Common Stock	Sell	Dispose S	No	No	0.58	6,688	3.88 k	33,007

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Wells Fargo Maintains Equal-Weight on Kezar Life Sciences, Lowers Price Target to $9

19 Dec 24

Wells Fargo analyst Derek Archila maintains Kezar Life Sciences (NASDAQ:KZR) with a Equal-Weight and lowers the price target from $11 to $9.

Press releases

From Benzinga Pro

Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025

18 Feb 25

Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will present at a